Bacteria engineered to treat a disease or disorder
Dean Falb, Sherborn, MA (US); Paul F. Miller, Salem, CT (US); Jonathan W. Kotula, Berkeley, CA (US); Vincent M. Isabella, Medford, MA (US); Suman Machinani, Monroe, NY (US); Adam B. Fisher, Cambridge, MA (US); and Yves Millet, Newton, MA (US)
Assigned to Synlogic Operating Company, Inc., Cambridge, MA (US)
Filed by Synlogic Operating Company, Inc., Cambridge, MA (US)
Filed on Dec. 17, 2020, as Appl. No. 17/124,661.
Application 17/124,661 is a continuation of application No. 15/852,762, filed on Dec. 22, 2017, granted, now 10,933,102.
Application 15/852,762 is a continuation of application No. 15/319,564, granted, now 9,889,164, issued on Feb. 13, 2018, previously published as PCT/US2016/032565, filed on May 13, 2016.
Application 15/319,564 is a continuation in part of application No. 15/154,934, filed on May 13, 2016, granted, now 10,610,546.
Application 15/154,934 is a continuation in part of application No. PCT/US2016/032562, filed on May 13, 2016.
Application PCT/US2016/032562 is a continuation in part of application No. PCT/US2016/020530, filed on Mar. 2, 2016.
Application PCT/US2016/020530 is a continuation in part of application No. 14/960,333, filed on Dec. 4, 2015, granted, now 9,487,764, issued on Nov. 8, 2016.
Application 14/960,333 is a continuation in part of application No. PCT/US2015/064140, filed on Dec. 4, 2015.
Claims priority of provisional application 62/336,338, filed on May 13, 2016.
Claims priority of provisional application 62/335,780, filed on May 13, 2016.
Claims priority of provisional application 62/336,012, filed on May 13, 2016.
Claims priority of provisional application 62/335,940, filed on May 13, 2016.
Claims priority of provisional application 62/314,322, filed on Mar. 28, 2016.
Claims priority of provisional application 62/313,691, filed on Mar. 25, 2016.
Claims priority of provisional application 62/293,749, filed on Feb. 10, 2016.
Claims priority of provisional application 62/277,654, filed on Jan. 12, 2016.
Claims priority of provisional application 62/277,413, filed on Jan. 11, 2016.
Claims priority of provisional application 62/277,346, filed on Jan. 11, 2016.
Claims priority of provisional application 62/263,329, filed on Dec. 4, 2015.
Claims priority of provisional application 62/256,039, filed on Nov. 16, 2015.
Claims priority of provisional application 62/256,041, filed on Nov. 16, 2015.
Claims priority of provisional application 62/256,052, filed on Nov. 16, 2015.
Claims priority of provisional application 62/212,223, filed on Aug. 31, 2015.
Claims priority of provisional application 62/199,445, filed on Jul. 31, 2015.
Claims priority of provisional application 62/183,935, filed on Jun. 24, 2015.
Claims priority of provisional application 62/173,710, filed on Jun. 10, 2015.
Claims priority of provisional application 62/173,761, filed on Jun. 10, 2015.
Claims priority of provisional application 62/173,706, filed on Jun. 10, 2015.
Claims priority of provisional application 62/161,137, filed on May 13, 2015.
Prior Publication US 2021/0169942 A1, Jun. 10, 2021
1. A method of producing a pharmaceutically acceptable composition comprising a genetically-engineered non-pathogenic bacterium for use in metabolizing phenylalanine, the bacterium comprising
at least one heterologous gene encoding a phenylalanine transporter for importing phenylalanine into the bacterium operably linked to a directly or indirectly inducible promoter that is not associated with the phenylalanine transporter in nature, and
at least one heterologous gene encoding a polypeptide involved in metabolizing phenylalanine operably linked to a directly or indirectly inducible promoter that is not associated with the at least one heterologous gene encoding the polypeptide in nature,
the method comprising the steps of:
a) growing the bacterium in a growth medium culture under conditions that do not induce the promoter that controls expression of the transporter for importing phenylalanine;
b) isolating the resulting bacteria from the growth medium; and
c) suspending the isolated bacteria in a pharmaceutically acceptable carrier.